newsfilter
← Latest News
Business Wire·

CytRx Highlights Strategic Purchase of Arimoclomol by KemPharm, Inc.

KemPharm Sees Promise in Arimoclomol for Niemann-Pick Disease Type C, and Plans to Resubmit to FDA as Early as Q1 2023 CytRx Corporation (OTCQB:CYTR) ("CytRx" or the "Company"), a biopharmaceutical innovator focused on research and development of lif